Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26–41.

Article  PubMed  CAS  Google Scholar 

Salphati L, Shahidi-Latham S, Quiason C, Barck K, Nishimura M, Alicke B, et al. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging. Drug Metab Dispos. 2014;42(7):1110–6.

Article  PubMed  Google Scholar 

Heffron TP. Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels. Neuro Oncol. 2018;20(3):307–12.

Article  PubMed  CAS  Google Scholar 

Steeg PS. The blood-tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol. 2021;18(11):696–714.

Article  PubMed  Google Scholar 

Trainor GL. The importance of plasma protein binding in drug discovery. Expert Opin Drug Discov. 2007;2(1):51–64.

Article  PubMed  CAS  Google Scholar 

Loryan I, Reichel A, Feng B, Bundgaard C, Shaffer C, Kalvass C, et al. Unbound brain-to-plasma partition coefficient, K(p, uu, brain)-a game changing parameter for CNS drug discovery and development. Pharm Res. 2022;39(7):1321–41.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Trapa PE, Belova E, Liras JL, Scott DO, Steyn SJ. Insights from an integrated physiologically based pharmacokinetic model for brain penetration. J Pharm Sci. 2016;105(2):965–71.

Article  PubMed  CAS  Google Scholar 

Feng B, West M, Patel NC, Wager T, Hou X, Johnson J, et al. Validation of human MDR1-MDCK and BCRP-MDCK cell lines to improve the prediction of brain penetration. J Pharm Sci. 2019;108(7):2476–83.

Article  PubMed  CAS  Google Scholar 

Jiang L, Kumar S, Nuechterlein M, Reyes M, Tran D, Cabebe C, et al. Application of a high-resolution in vitro human MDR1-MDCK assay and in vivo studies in preclinical species to improve prediction of CNS drug penetration. Pharmacol Res Perspect. 2022;10(1):e00932.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117(2):333–45.

Article  PubMed  CAS  Google Scholar 

Hoshi Y, Uchida Y, Tachikawa M, Inoue T, Ohtsuki S, Terasaki T. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J Pharm Sci. 2013;102(9):3343–55.

Article  PubMed  CAS  Google Scholar 

Li N, Kulkarni P, Badrinarayanan A, Kefelegn A, Manoukian R, Li X, et al. P-glycoprotein substrate assessment in drug discovery: application of modeling to bridge differential protein expression across in vitro tools. J Pharm Sci. 2021;110(1):325–37.

Article  PubMed  CAS  Google Scholar 

Braun C, Sakamoto A, Fuchs H, Ishiguro N, Suzuki S, Cui Y, et al. Quantification of transporter and receptor proteins in dog brain capillaries and choroid plexus: relevance for the distribution in brain and CSF of selected BCRP and P-gp substrates. Mol Pharm. 2017;14(10):3436–47.

Article  PubMed  CAS  Google Scholar 

Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci. 2011;100(9):3939–50.

Article  PubMed  CAS  Google Scholar 

Demeule M, Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer. 2001;93(1):62–6.

Article  PubMed  CAS  Google Scholar 

Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med. 2011;13:e17.

Article  PubMed  PubMed Central  Google Scholar 

Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16(23):5664–78.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang W, Vaubel RA, Oh JH, Mladek AC, Talele S, Zhang W, et al. Delivery versus potency in treating brain tumors: BI-907828, a MDM2-p53 antagonist with limited BBB penetration but significant in vivo efficacy in glioblastoma. Mol Cancer Ther. 2024;23(1):47–55.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Huang L, Be X, Tchaparian EH, Colletti AE, Roberts J, Langley M, et al. Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats. J Pharmacol Exp Ther. 2012;343(2):316–24.

Article  PubMed  CAS  Google Scholar 

Howard ML, Hill JJ, Galluppi GR, McLean MA. Plasma protein binding in drug discovery and development. Comb Chem High Throughput Screen. 2010;13(2):170–87.

Article  PubMed  CAS  Google Scholar 

Wang M, Kuldharan S, Shenoy A, Reddy S, Rex K, Osgood T, et al. Xenografted tumors share comparable fraction unbound and can be surrogated by mouse lung tissue. Drug Metab Dispos. 2024;52(7):644–53.

Article  PubMed  CAS  Google Scholar 

Hughes CS, Moggridge S, Muller T, Sorensen PH, Morin GB, Krijgsveld J. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc. 2019;14(1):68–85.

Article  PubMed  CAS  Google Scholar 

MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pino LK, Searle BC, Bollinger JG, Nunn B, MacLean B, MacCoss MJ. The Skyline ecosystem: informatics for quantitative mass spectrometry proteomics. Mass Spectrom Rev. 2020;39(3):229–44.

Article  PubMed  CAS  Google Scholar 

Storelli F, Anoshchenko O, Unadkat JD. Successful prediction of human steady-state unbound brain-to-plasma concentration ratio of P-gp substrates using the proteomics-informed relative expression factor approach. Clin Pharmacol Ther. 2021;110(2):432–42.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sato S, Matsumiya K, Tohyama K, Kosugi Y. Translational CNS steady-state drug disposition model in rats, monkeys, and humans for quantitative prediction of brain-to-plasma and cerebrospinal fluid-to-plasma unbound concentration ratios. AAPS J. 2021;23(4):81.

Article  PubMed  CAS  Google Scholar 

Vlaming ML, van Esch A, van de Steeg E, Pala Z, Wagenaar E, van Tellingen O, Schinkel AH. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metab Dispos. 2011;39(8):1338–44.

Article  PubMed  CAS  Google Scholar 

Workman MJ, Svendsen CN. Recent advances in human iPSC-derived models of the blood-brain barrier. Fluids Barriers CNS. 2020;17(1):30.

Article  PubMed  PubMed Central  Google Scholar 

Rambeck B, Jurgens UH, May TW, Pannek HW, Behne F, Ebner A, et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia. 2006;47(4):681–94.

Article  PubMed  CAS